CSL Ltd Annual Report 2021

* Limited assurance by Ernst & Young. Business performance highlights Focus • Remained focused on delivering on our promise to patients and public health during an unprecedented time of uncertainty. • US$20.2 million supporting product access across the world.* Innovation • Research and development (R&D) investment of US$1 billion.* • Acquired the exclusive global licence rights to a late stage gene therapy candidate for the treatment of haemophilia B. • CSL112 (currently in Phase III for cardiovascular disease) continues to progress with over 13,000 patients enrolled. • Commenced a Phase II study for an adjuvanted QIV cell-based influenza vaccine. • Accelerated research into self-amplifying mRNA technology to develop the potential next generation of influenza vaccines. • Achieved 28 product registrations or new indications across the globe. • US$55.2 million in global community investment across our strategic areas of support. Efficiency and reliable supply • Ongoing investment in major capital projects at all manufacturing sites to support future growth. • In 2020/21, 25 new plasma collection centres opened. • Record number of influenza vaccine doses distributed by Seqirus. • Delivering on our agreements to supply 50 million doses of the AstraZeneca COVID-19 vaccine. • Participated in 365 successful regulatory inspections of our manufacturing facilities.* Sustainable growth • A strong year of growth with revenue up 10% and reported net profit after tax of $2,375 million, up 10% at constant currency. • Strong performance by HIZENTRA ® , our market leading subcutaneous immunoglobulin product with sales up 15%. • Seqirus revenue up 30% at constant currency driven by strong growth in seasonal influenza vaccines. • US$9.9 billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions.* • Release of CSL Group Sustainability Strategy. Digital transformation • Appointment of Chief Digital and Information Officer. • New initiatives and technology implemented at plasma collection centres. • New enterprise-wide digital platform rollout. People and culture • Achieved 73.7% employee engagement* score, on par with the previous year. • 43% female representation at Board level, 57% female across the Group. • Launched a new Promising Futures Scholarship Program to provide financial assistance to US employees and their dependants. Patients and Public Health underpin everything we do CSL Limited Annual Report 2020/21 6 2 2021 Performance